Study design
In this randomized prospective study were included patients that were submitted to Spatz3® (Genco et al., 2013)[2] (Spatz ABS—Spatz FGIA, Inc., Jericho, NY, USA).
adjustable IGB treatment between October 2016 and June 2018 in a private clinic (EndogastroRio) in Rio de Janeiro/Brazil.